Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neola Medical AB's revenue for the
three
months ended in Jun. 2026 was kr0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was kr0.00 Mil.
Neola Medical AB's Revenue per Share for the
three
months ended in Jun. 2026 was kr0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was kr0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Neola Medical AB's highest 3-Year average Revenue per Share Growth Rate was -13.30% per year. The lowest was -13.30% per year. And the median was -13.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Neola Medical AB Revenue Related Terms
Neola Medical AB Revenue Historical Data
* Premium members only.
The historical data trend for Neola Medical AB's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Neola Medical AB's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neola Medical AB Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neola Medical AB's Revenue distribution charts can be found below:
* The bar in red indicates where Neola Medical AB's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neola Medical AB (OSTO:NEOLA) has a Revenue of kr0.00 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Neola Medical AB and its competitors.
Is Neola Medical AB's Revenue too high?
Neola Medical AB's current Revenue is kr0.00 Mil. Overall, Neola Medical AB has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Neola Medical AB's Revenue compare to ABT and SYK?
Neola Medical AB's Revenue of kr0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Neola Medical AB and its competitors. Neola Medical AB's current Revenue is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neola Medical AB stock overvalued right now?
Neola Medical AB (OSTO:NEOLA) has a current Revenue of kr0.00 Mil. The current Revenue is kr0.00 Mil. Neola Medical AB's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Neola Medical AB (OSTO:NEOLA), the current Revenue is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neola Medical AB is revolutionizing neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a technology that measures lung volume changes and oxygen gas concentration. NEOLA has the potential to provide care, fewer days in intensive care, and healthier lives for preterm born infants. The company is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to health care.
21GF Score
Get the complete analysis for OSTO:NEOLA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEOLA has been successfully added to your 
